Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Hold” by Analysts

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $42.2222.

SION has been the topic of a number of recent research reports. Lifesci Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Wall Street Zen downgraded Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Guggenheim lowered shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. JonesTrading cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Finally, Citizens Jmp downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 85,918 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 403,726 shares of company stock valued at $18,259,354 in the last ninety days. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics during the 3rd quarter worth $30,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the second quarter valued at about $31,000. State of Wyoming purchased a new position in Sionna Therapeutics in the second quarter valued at about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sionna Therapeutics in the second quarter worth about $44,000. Finally, Balyasny Asset Management L.P. bought a new position in Sionna Therapeutics in the fourth quarter worth about $58,000.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $5.94 on Wednesday. The company has a market capitalization of $268.55 million, a PE ratio of -2.72 and a beta of 1.32. The company has a 50 day moving average price of $38.07 and a 200-day moving average price of $38.64. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts forecast that Sionna Therapeutics will post -2.55 earnings per share for the current year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.